Colorado-based Mary’s Medicinals announced today in a press release that it has been awarded a U.S. patent for its transdermal cannabinoid gel technology.
“We might be the first legal cannabis company in the United States to have a patented product formulation currently available to consumers,” Graham Sorkin, Director of Business Development at Mary’s Medicinals, told Ganjapreneur.
Through Mary’s four unique transdermal gel formulations — THC Indica, THC Sativa, CBN and CBD — consumers have an accurate and discreet way of consuming medical cannabis products. Mary’s also offers CBD Transdermal Gel Pens that have been manufactured through its sister company, Mary’s Nutritionals.
“We are pleased that the Patent and Trademark Office has approved our application,” said founder and CEO Nicole Smith in a statement issued by Mary’s Medicinals today. “The PTO has only granted an extremely limited number of cannabis-related patents — almost exclusively to major international pharmaceutical corporations, research institutions and the Federal Government.
Mary’s Medicinals started as a medical cannabis flagship company in Colorado and has since expanded to markets in Washington, California, Oregon, Vermont and Arizona.
“As a small startup company, securing this protection for our intellectual property and the recognition of the uniqueness of our offerings will bolster our continued leadership in this rapidly growing industry,” Smith said.
According to the press release:
The patent application (U.S. Patent Application Serial No.14/561,091), which is owned by Mary’s Medicinals, was filed on Dec. 4, 2014 by inventor Nicole Smith. Mary’s Chief Scientist, Noel Palmer, Ph.D. is also listed as an inventor. Mary’s Medicinals has additional patent applications filed and pending for its other unique cannabis products.
Get daily cannabis business news updates. Subscribe